Scpharmaceuticals Inc (SCPH) - Total Liabilities
Based on the latest financial reports, Scpharmaceuticals Inc (SCPH) has total liabilities worth $101.57 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SCPH asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Scpharmaceuticals Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Scpharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SCPH asset base.
Scpharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Scpharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dongsung FineTec Co. Ltd
KQ:033500
|
Korea | ₩224.84 Billion |
|
Vitruvio Real Estate Socimi
MC:YVIT
|
Spain | €104.37 Million |
|
PETROTAL CORP.
F:SER1
|
Germany | €289.88 Million |
|
Rimini Street Inc
NASDAQ:RMNI
|
USA | $380.14 Million |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
China | CN¥681.04 Million |
|
Neuberger Berman IMF Inc
NYSE MKT:NBH
|
USA | $231.69 Million |
|
Vysarn Ltd
AU:VYS
|
Australia | AU$31.93 Million |
|
Value Line Inc
NASDAQ:VALU
|
USA | $43.20 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Scpharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Scpharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.77 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scpharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scpharmaceuticals Inc (2015–2024)
The table below shows the annual total liabilities of Scpharmaceuticals Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $94.20 Million | +64.51% |
| 2023-12-31 | $57.26 Million | +10.62% |
| 2022-12-31 | $51.76 Million | +129.37% |
| 2021-12-31 | $22.57 Million | -16.04% |
| 2020-12-31 | $26.88 Million | +3.70% |
| 2019-12-31 | $25.92 Million | +72.66% |
| 2018-12-31 | $15.01 Million | -6.48% |
| 2017-12-31 | $16.05 Million | -79.11% |
| 2016-12-31 | $76.85 Million | +282.58% |
| 2015-12-31 | $20.09 Million | -- |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more